About

Launched in 2019, BrightEdge is the American Cancer Society’s mission-driven venture capital fund. The fund invests in for-profit companies developing novel cancer-focused treatments.

About

Launched in 2019, BrightEdge is the American Cancer Society’s mission-driven venture capital fund. The fund invests in for-profit companies developing novel cancer-focused treatments.

Our Mission

Leading the fight for a world without cancer.
BrightEdge’s goal is to accelerate market delivery of innovative oncology treatments through capital investment, market awareness, and a shared commitment to eradicate cancer.
Our Connection
While the American Cancer Society focuses on discovering tomorrow’s treatments, BrightEdge focuses on accelerating market adoption to innovations today. BrightEdge leverages the extensive scientific expertise of the American Cancer Society and other investment experts to diligence potential investments and offer support to portfolio companies.
American Cancer Society Logo

$4.8b

Invested in Research Since 1946

49

Noble Laureates

27%

Decline in Mortality Rate

Investing for Real Impact

A portion of donations to the ACS are dedicated to BrightEdge annually to invest in companies poised to have real impact on lives. By supporting innovation that is nearing market-readiness, we strive to reach a world without cancer sooner.

Reinvested Returns

BrightEdge returns are reinvested with the goal of ultimately creating a sustainable stream of capital to fund other critical ACS initiatives that dramatically improve the lives of cancer patients and their loved ones.

BrightEdge Portfolio Companies are...

  • Attacking Cancer

    BrightEdge portfolio companies must have a substantial focus on oncology. We may invest in companies that have non-oncology applications, but the primary value proposition must be overwhelmingly in oncology.
  • Focused on Therapeutics

    BrightEdge primarily focuses on therapeutics companies. We will consider any therapeutic modality that has the potential to improve outcomes for cancer patients
  • In All Stages of Development

    BrightEdge is stage-agnostic and will invest in seed-stage companies, businesses raising crossover rounds, and everything in between.
  • Funded by Industry-Leading VCs

    BrightEdge invests alongside the industry’s top VC funds to accelerate the most innovative companies that are raising capital through equity or convertible debt. (Note that while ACS Research distributes over one hundred million dollars of translational grants per year, the BrightEdge fund does not provide grant funding.)